Ropeginterferon alfa-2b

 

Category:

Exhibitor: PHARMAESSENTIA CORP.

Booth No: L118

 

Characteristic

 

In the field of protein drug design, the process of pegylation of the therapeutic protein preserves its biologic activity by targeting the PEG polymer (polyethylene glycol) at a specific and a defined region on the protein. PharmaEssentia’s pegylation technology platform is designed to increase the protein drug’s efficacy by prolonging its circulation in the blood stream. Utilizing its innovative 40K PEG and its novel pegylation technology platform by combining protein engineering and PEG-related chemistry, PharmaEssentia creates novel product- Ropeginterferon alfa-2b for better disease treatment. Compared with similar drugs on the market, the long-acting, mono-pegylated proline interferon with improved pharmacokinetic properties allowing once every two weeks administration offering improved tolerability and convenience. The marketing authorization for Ropeginterferon alfa-2b for treatment of Polycythemia Vera (PV) is granted by EMA in February 2019, Taiwan in May 2020, Korea in October 2021, FDA in November 2021 and Japan in March 2023.

 

Other Products

 

• 

  Tirbanibulin

 

 

Back